Journal article
Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction
Abstract
The efficacy and safety of recombinant tissue plasminogen activator (rt-PA) administered on a dosing per weight basis was evaluated in a randomized, placebo-controlled, double-blind trial in 115 patients with acute myocardial infarction. The principal outcomes were global and regional left ventricular function in the distribution of the qualifying myocardial infarction, determined 9 days after the onset of symptoms. Global and regional ejection …
Authors
Armstrong PW; Baigrie RS; Daly PA; Haq A; Gent M; Roberts RS; Freeman MR; Burns R; Liu P; Morgan CD
Journal
Journal of the American College of Cardiology, Vol. 13, No. 7, pp. 1469–1476
Publisher
Elsevier
Publication Date
June 1989
DOI
10.1016/0735-1097(89)90334-3
ISSN
0735-1097